Friday - July 25, 2025

LOGIN  |  REGISTER
Amneal Pharmaceuticals

HCA Healthcare to Present at September Healthcare Conferences

August 12, 2024 | Last Trade: US$341.48 11.79 -3.34

NASHVILLE, Tenn. / Aug 12, 2024 / Business Wire / HCA Healthcare, Inc. (NYSE: HCA), is scheduled to present at the following healthcare conferences:

September 5, 2024 at 8:00am ET at the 2024 Wells Fargo Healthcare Conference at the Encore Boston Arbor in Everett, MA.

September 5, 2024 at 3:20pm ET at Morgan Stanley’s 22nd Annual Global Healthcare Conference at the Marriott Marquis in New York, NY.

A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company’s website, www.hcahealthcare.com.

Dates and times may be subject to change, please check the conference schedule or the Investor Relations section of the Company’s website for the latest information.

About HCA Healthcare

Nashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 188 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom.

All references to “Company” and “HCA” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.

Recursion

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page